Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide–Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

Heather Eng, Renato J. Scialis, Charles J. Rotter, Jian Lin, Sarah Lazzaro, Manthena V. Varma, Li Di, Bo Feng, Michael West and Amit S. Kalgutkar
Drug Metabolism and Disposition May 2016, 44 (5) 692-699; DOI: https://doi.org/10.1124/dmd.115.067447
Heather Eng
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renato J. Scialis
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles J. Rotter
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Lin
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Lazzaro
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manthena V. Varma
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Di
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Feng
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael West
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit S. Kalgutkar
Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 44 no. 5 692-699
DOI 
https://doi.org/10.1124/dmd.115.067447
PubMed 
26888941

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received September 28, 2015
  • Accepted February 12, 2016
  • Published online April 5, 2016.

Article Versions

  • Earlier version (February 17, 2016 - 08:16).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Heather Eng,
  2. Renato J. Scialis,
  3. Charles J. Rotter,
  4. Jian Lin,
  5. Sarah Lazzaro,
  6. Manthena V. Varma,
  7. Li Di,
  8. Bo Feng,
  9. Michael West, and
  10. Amit S. Kalgutkar
  1. Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Groton, Connecticut (H.E., R.J.S., C.J.R., J.L., S.L., M.V.V., L.D., B.F., M.W.); and Pharmacokinetics, Pharmacodynamics, and Metabolism Department–New Chemical Entities, Pfizer Inc., Cambridge MA (A.S.K.)
  1. Address correspondence to:
    Amit S. Kalgutkar, Pharmacokinetics, Dynamics, and Metabolism–New Chemical Entities, Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, MA 02139. E-mail: amit.kalgutkar{at}pfizer.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: February 2016 to January 2021

AbstractFullPdf
Feb 20165290116
Mar 2016189069
Apr 20168501763
May 20162932457
Jun 20161761937
Jul 2016117827
Aug 201672513
Sep 20164638
Oct 2016692328
Nov 2016481312
Dec 2016461112
Jan 2017451311
Feb 201723915
Mar 201733116
Apr 201783243
May 201763629
Jun 201762323
Jul 201713025
Aug 201783023
Sep 2017050518
Oct 2017034023
Nov 201725018
Dec 201723420
Jan 201803820
Feb 201802514
Mar 201803722
Apr 201804920
May 201814611
Jun 201804617
Jul 201806321
Aug 20180557
Sep 20181368
Oct 201852920
Nov 20182238
Dec 20183488
Jan 201942220
Feb 20190177
Mar 201931320
Apr 201956630
May 201922925
Jun 201992941
Jul 201901927
Aug 201902224
Sep 201942128
Oct 201932037
Nov 201922413
Dec 20195177
Jan 202042531
Feb 202012239
Mar 202063238
Apr 202033170
May 202022730
Jun 202012025
Jul 202021722
Aug 202011438
Sep 202062538
Oct 202004228
Nov 202061624
Dec 2020101433
Jan 202172240

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 44 (5)
Drug Metabolism and Disposition
Vol. 44, Issue 5
1 May 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide–Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Drug–Drug Interaction between Statins and Fusidic Acid

Heather Eng, Renato J. Scialis, Charles J. Rotter, Jian Lin, Sarah Lazzaro, Manthena V. Varma, Li Di, Bo Feng, Michael West and Amit S. Kalgutkar
Drug Metabolism and Disposition May 1, 2016, 44 (5) 692-699; DOI: https://doi.org/10.1124/dmd.115.067447

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Drug–Drug Interaction between Statins and Fusidic Acid

Heather Eng, Renato J. Scialis, Charles J. Rotter, Jian Lin, Sarah Lazzaro, Manthena V. Varma, Li Di, Bo Feng, Michael West and Amit S. Kalgutkar
Drug Metabolism and Disposition May 1, 2016, 44 (5) 692-699; DOI: https://doi.org/10.1124/dmd.115.067447
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • BSEP Function in Suspension Hepatocytes
  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics